Oncolytics Biotech Unveils Data Showing Pelareorep’s Immune-Priming Potential at AACR 2026
Event summary
- Oncolytics Biotech will present two abstracts at AACR 2026, showcasing pelareorep’s ability to drive immune activation and tertiary lymphoid structure formation.
- Biomarker data from the GOBLET trial suggest pelareorep plus atezolizumab and chemotherapy can shift pancreatic cancer tumors toward a more immune-active state.
- AWARE-1 data reveal pelareorep’s potential to convert immunologically ‘cold’ tumors into immune-responsive ‘hot’ tumors through TLS formation.
- Pelareorep demonstrated a 62% objective response rate in first-line metastatic pancreatic ductal adenocarcinoma patients, more than double the response rates historically observed with chemotherapy alone.
The big picture
Oncolytics Biotech’s upcoming presentations at AACR 2026 highlight the growing evidence supporting pelareorep as an immune-priming agent capable of enhancing the activity of multiple therapeutic classes. The data suggest potential to address significant unmet needs in oncology, particularly in RAS-driven tumors like pancreatic and colorectal cancers. The company’s focus on combination therapies and biomarker-driven approaches aligns with broader industry trends toward personalized and immuno-oncology treatments.
What we're watching
- Clinical Validation
- Whether the AACR 2026 data will further validate pelareorep as a foundational backbone for combination therapy across multiple tumor types.
- Regulatory Progress
- The pace at which Oncolytics advances its registrational programs in gastrointestinal cancers, particularly given the FDA’s Fast Track designation for colorectal and pancreatic cancer.
- Strategic Partnerships
- How Oncolytics’ pursuit of strategic partnerships will accelerate the development and commercial impact of pelareorep.
Related topics